Looking for Lilly’s LY4086940? Its two registered trials, NCT06945419 and NCT07890376, are listed below. For what they test and what has not been disclosed, see the LY4086940 profile or our LY4086940 write-up.
5 registered trials, newest registry update first. Showing only trials linked to Larazotide.
| Trial | Compound | Phase | Status | Sponsor | Enrolled | Primary completion | Registry updated |
|---|---|---|---|---|---|---|---|
| AT1001 for the Treatment of Long COVID NCT05747534 | Larazotide | Phase 2 | Completed | Massachusetts General Hospital | 107 | Jun 18, 2026 | Aug 18, 2026 |
| AT1001 for the Treatment of COVID-19 Related MIS-C NCT05022303 | Larazotide | Phase 2 | Terminated | Massachusetts General Hospital | 12 | May 15, 2024 | Jun 13, 2024 |
| Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms NCT03569007 | Larazotide | Phase 3 | Terminated | 9 Meters Biopharma, Inc. | 307 | Jul 21, 2022 | Jul 26, 2022 |
| Study of the Efficacy of Larazotide Acetate to Treat Celiac Disease NCT00889473 | Larazotide | Phase 2 | Completed | 9 Meters Biopharma, Inc. | 42 | Nov 2009 | Sep 20, 2017 |
| A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease NCT01396213 | Larazotide | Phase 2 | Completed | 9 Meters Biopharma, Inc. | 342 | Aug 20, 2013 | Sep 20, 2017 |
Data: ClinicalTrials.gov, U.S. National Library of Medicine. Registered trials only. This table does not report results or recommend anything.